Medical Facility
Tempe, Arizona, 85283, United States
NCT Number: NCT04421885
A bioequivalence and food-effect study comparing two tablet formulations of tebipenem pivoxil hydrobromide (TBPM-PI-HBr) in healthy adult subjects.
Looking for future studies?
Notify Me18 year–55 year
All sexes
Interventional
Phase 1
Tempe, Arizona, 85283, United States
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
600 mg (2 x 300 mg tablets) clinical study drug product batch TBPM-PI-HBr.
600 mg (2 x 300 mg tablets) registration drug product batch TBPM-PI-HBr.
Time frame: 24h (Day 2) post dose (Arms: A, B, C)
Time frame: 24h (Day 2) post dose (Arms: A, B, C)
Time frame: 24h (Day 2) post dose (Arms: A, B, C)
Time frame: 24h (Day 2) post dose (Arms: A, B, C)
Time frame: 24h (Day 2) post dose (Arms: A, B, C)
Time frame: 24h (Day 2) post dose (Arms: A, B, C)
Time frame: 24h (Day 2) post dose (Arms: A, B, C)
Time frame: 12 to 14 days after the last dose of study drug
ECG, Clinical Laboratories, Vitals Signs and Physical Exams will be used as a safety measure to detect any AEs.
Time frame: 24h (Day 2) post dose (Arms: B, C)
TPBM PK parameters following administration of the TBPM-PI-HBr Test tablet under fasted and fed conditions.
Time frame: 24h (Day 2) post dose (Arms: B, C)
TPBM PK parameters following administration of the TBPM-PI-HBr Test tablet under fasted and fed conditions.
Time frame: 24h (Day 2) post dose (Arms: B, C)
TPBM PK parameters following administration of the TBPM-PI-HBr Test tablet under fasted and fed conditions.
Time frame: 24h (Day 2) post dose (Arms: B, C)
TPBM PK parameters following administration of the TBPM-PI-HBr Test tablet under fasted and fed conditions.
Time frame: 24h (Day 2) post dose (Arms: B, C)
TPBM PK parameters following administration of the TBPM-PI-HBr Test tablet under fasted and fed conditions.
Time frame: 24h (Day 2) post dose (Arms: B, C)
TPBM PK parameters following administration of the TBPM-PI-HBr Test tablet under fasted and fed conditions.
Time frame: 24h (Day 2) post dose (Arms: B, C)
TPBM PK parameters following administration of the TBPM-PI-HBr Test tablet under fasted and fed conditions.
Spero Therapeutics
Industry
An Open-Label, Randomized, Single-Dose, Semi-Replicate, 4-Period, Crossover, Bioequivalence Study Comparing Two Tablet Formulations of Tebipenem Pivoxil Hydrobromide (TBPM-PI-HBr) in Healthy Adult Subjects
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT05447078
Healthy Volunteers, Infections
Jackson, Mississippi, United States
View Trial DetailsNCT07513532
Healthy Volunteers
Seattle, Washington, United States
View Trial DetailsNCT07090655
Healthy Volunteers
Brisbane, Australia
View Trial DetailsNCT01915212
Communicable Diseases, DNA Virus Infections
Bethesda, Maryland, United States
View Trial Details